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Background: Health care utilization and costs among US veterans with chronic obstructive 
pulmonary disease (COPD) were compared with those in veterans without COPD.
Methods: A cohort of veterans with COPD was matched for age, sex, race, and index fiscal 
year to a cohort of veterans without COPD (controls) using data from the Veterans Integrated 
Service Network (VISN) 16 from 10/1/1997 to 9/30/2004. Annual total and respiratory-related 
health care service utilization, costs of care, comorbidities, and respiratory medication use at 
the time of diagnosis were assessed.
Results: A total of 59,906 patients with COPD were identified for a 7-year period prevalence of 
8.2%, or 82 per 1000 population. Patients with COPD compared with controls had significantly 
higher all-cause and respiratory-related inpatient and outpatient health care utilization for 
every parameter examined including mean numbers of physician encounters, other outpatient 
encounters, emergency room visits, acute inpatient discharges, total bed days of care, and 
percentage of patients with any emergency room visits or any acute inpatient discharge. Patients 
with COPD had statistically significantly higher mean outpatient, inpatient, pharmacy, and total 
costs than the control group. The mean Charlson comorbidity index in patients with COPD 
was 1 point higher than in controls (2.85 versus 1.84, P  0.001). 60% of COPD patients were 
prescribed medications recommended in treatment guidelines at diagnosis.
Conclusion: Veterans with COPD compared with those without COPD suffer a tremendous 
disease burden manifested by higher rates of all-cause and respiratory-related health care 
utilization and costs and a high prevalence of comorbidities. Furthermore, COPD patients do 
not receive appropriate treatment for their disease on diagnosis.
Keywords: chronic obstructive pulmonary disease (COPD), veterans, health care utilization, 
costs, respiratory medicine, VA, economic burden, burden of illness
Chronic obstructive pulmonary disease (COPD) may be a particularly significant health 
concern among military veterans. COPD is common in veterans and was a primary cause 
of mortality, second only to cancer and vascular disease, in a cohort of retired military 
Chinese veterans followed over an 18-year period.1 The high prevalence of COPD 
among veterans might be attributed to the strong association between combat experience 
and health risk behaviors including smoking,2 which is the major cause of COPD. The 
Department of Veterans Affairs (VA) – one of the largest managed care organizations in 
the United States – is integrally involved in the care of veterans with COPD. Each year, 
the VA provides care for approximately 500,000 patients with a diagnosis of COPD,3 
and COPD is among the most common discharge diagnoses from VA hospitals.4
The VA health care system differs from other sectors of health care in the USA and 
resembles some of the international health care systems. Firstly, there are established International Journal of COPD 2010:5 126
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enrollment eligibility criteria for use of the system. Secondly, 
the system does not provide incentives to the practitioners for 
under- or over utilization of health care resources. Thirdly, 
various specialists within the system review the literature and 
  provide evidence-based guidelines for delivery of health care. 
Fourthly, due to its size, the VA health care system allows 
for negotiation of prices for various health care items at a 
significantly discounted level that can results in more cost 
effective delivery of health care systems. Finally, VA facilities 
uniquely represent a wide range of practice settings including 
academic and nonacademic hospitals and community-based 
health care facilities and thus diagnostic and treatment deci-
sions are made by a variety of health care providers including 
pulmonologists, primary care providers, and allied health 
practitioners. The study of the burden of COPD in this system 
may provide information that can validly be applied to wide 
range of health delivery systems internationally.
The importance of the VA system to COPD care 
  notwithstanding, little is known about health care utilization 
and health care costs in VA patients with COPD. The research 
that has been conducted suggests that VA patients with 
COPD frequently have other serious comorbid diseases, 
are significant users of health care resources, and are not 
being managed according to treatment guidelines.3–7 The 
study described herein, which involved a large sample 
of VA patients in the southwestern United States, was 
conducted to examine health care utilization and costs to 
the VA for patients with COPD compared with veterans 
without COPD. To the authors’ knowledge this study is the 
first large-scale assessment specifically aimed at assessing 
health care use and costs associated with COPD in the VA 
patient population.
Method
The protocol for this segmented, historical, retrospective, 
matched-cohort study was approved by the Baylor College 
of Medicine Institutional Review Board and the Michael E. 
DeBakey VA Medical Center Research and Development 
Review Committee. This study included data collected 
between 1 October 1997 and 30 September 2004.
Data source
Data were obtained from the VA Veterans Integrated Service 
Network (VISN) 16 Database Warehouse, a repository of 
administrative and clinical data from 10 Departments of VA 
medical centers in the south central United States. The VISN 16 
Database Warehouse contains more than 759 million electronic 
medical records on more than 1.8 million patients. During the 
current study, 729,347 patients were treated for all conditions 
in the inpatient and outpatient facilities of VISN 16.
The VISN 16 Database Warehouse includes hospital 
discharge abstracts, data on outpatient clinic visits, pharmacy 
prescription fill records, and costs of care. The inpatient, 
outpatient, pharmacy, and cost data are computerized for 
each patient at local VA medical centers and are aggregated 
at the VISN level into the Database Warehouse.
Sample
Patients were eligible for the COPD group if they had a 
primary or secondary diagnosis of COPD based on the 
  International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) codes of 491.xx (chronic 
bronchitis), 492.xx (emphysema), 494.xx (bronchiecstasis), 
495.xx (allergic alveolitis), or 496.xx (chronic airway 
obstruction). The ICD-9-CM codes of 494.xx and 495.xx 
were allowed only if there were other COPD codes in other 
diagnosis fields. It is notable that very few COPD patients 
had only 494.xx or only 495.xx as stand-alone diagnoses. 
These two conditions, which generally are not used to define 
COPD, are relatively rare in patients with COPD and do not 
respond well to COPD medications including bronchodila-
tors and inhaled steroids. Patients with bronchiectasis usually 
  present with frequent infections and airflow obstruction and 
are treated similarly to patients with COPD. Patients with 
allergic alveolitis usually present with symptoms similar 
to those of COPD. More importantly, COPD patients with 
asthma diagnoses were excluded. The index date was defined 
as the first date of COPD diagnosis. Patients with ICD-9-
CM codes for other respiratory conditions including asthma, 
interstitial fibrosis, sarcoidosis, pulmonary hypertension, 
and pulmonary embolism, along with patients diagnosed 
with cancer other than skin nonmelanoma cancer were 
excluded.
For each COPD case, two patients without COPD were 
randomly selected to form the control group, which was 
matched to patients with COPD with respect to age, race/
ethnicity, sex, year in which the index diagnosis was made, 
and whether the index diagnosis was made in the inpatient 
or outpatient setting. Patients with any chronic respiratory 
condition were excluded from the control group.
Measures and data analyses
Measures included annual total and disease-specific related 
health care service utilization, costs of care, total illness 
burden, and use of respiratory medications at the time of 
COPD diagnosis.International Journal of COPD 2010:5 127
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Outpatient utilization included the numbers of physician 
encounters (nonlaboratory visits), nonphysician outpatient 
encounters, and emergency room visits. Inpatient utilization 
included acute inpatient discharges and total bed days of care 
for inpatient stays. These measures were stratified according 
to whether or not they were related to respiratory causes. 
Cost of care was examined for each category of outpatient 
and inpatient health care utilization. Pharmacy costs were 
summed for all pharmacy services. Respiratory-related health 
care utilization and costs were examined for the time period 
from 366 to 730 days following the patient’s index date, 
defined as the first date at which COPD was listed as a first or 
  second diagnosis in either the inpatient or outpatient setting 
for patients with COPD and as the date of the encounter at 
which the patient was matched with a corresponding COPD 
patient for controls. Costs were examined beginning 366 days 
after index. Patients with an index date before 10/1/1998 
were not included in these analyses because cost data were 
only available from 10/1/1999. Health care resource use 
was defined as respiratory-related if it involved the same 
ICD-9-CM codes used to define the population of COPD. 
This methodology is commonly accepted in retrospective 
  observational studies whereby costs associated with a medical 
claim in the administrative database are attributed to the 
primary/secondary diagnosis on that claim.
Total illness burden for each patient was determined by 
constructing the Deyo-adapted version of the Charlson Comor-
bidity Index.8 For each patient, all inpatient discharges and all 
outpatient visit records were searched for one year prior to index 
date to determine the presence of 17 comorbid conditions, 
identified using corresponding ICD-9-CM diagnosis codes, 
comprising the Charlson Comorbidity Index components.8 
The comorbidity index was constructed for each patient using 
the sum of the weighted values. Indicator variables for the 
following 13 comorbid conditions of interest were similarly 
created: depression; angina; cardiac dysrhythmias; pulmonary 
embolism; pneumonia; acute upper respiratory infection; otitis 
media; disorders of lipid metabolism; hypertension; osteoporo-
sis; gastroesophageal reflux disease; septicemia; alcohol/drug 
abuse, dependence, or poisoning.
Respiratory medication use in the following therapeutic 
categories was examined for the patients with COPD: inhaled 
corticosteroids; long- or short-acting beta-agonists; long- or 
short-acting anticholinergics; and inhaled corticosteroids/
long-acting beta-agonists combination agonists. All 
  prescriptions filled within 90 days prior to or after the index 
date were searched for use of these classes of medications.
Bivariate comparisons between patients with COPD and 
control patients were made for all demographic measures, 
measures of utilization and costs, the Charlson Comorbidity 
Index and individual Charlson comorbidities, and the 13 
additional comorbidities using t-tests and Chi-square tests 
as appropriate.
Results
Baseline demographics
A total of 59,906 patients with COPD were identified for 
a 7-year period prevalence of 8.2% and were matched 
to 117,546 patients without COPD (Table 1). Mean age, 
  gender, sex, and race/ethnicity distributions were comparable 
between patients with COPD and controls.
health care utilization and costs
Patients with COPD compared with controls had statistically 
significantly greater inpatient and outpatient health care 
Table 1 Baseline demographics
COPD patients (N = 59,906) Control patients (N = 117,546) P value
Mean age, years (SD) 65.63 (11.24) 65.52 (11.77) 0.074
Age group, n (%)
  40 years 833 (1.39) 2025 (1.72) 0.0001
  40 to 54 years 9968 (16.64) 19,538 (16.62)
  55 to 64 years 14,821 (24.74) 29,432 (25.04)
  65 to 74 years 19,778 (33.02) 36,538 (31.08)
  75+ years 14,506 (24.21) 30,013 (25.53)
Male, n (%) 58,579 (97.78) 114,904 (97.75) 0.6616
race, n (%)
  White 42,346 (70.69) 82,486 (70.17) 0.2801
  Black 8366 (13.97) 16,687 (14.20)
  hispanic 362 (0.60) 717 (0.61)
  Other 270 (0.45) 535 (0.46)
  Missing/unknown 8562 (14.29) 17,121 (14.57)
Abbreviations: COPD, chronic obstructive pulmonary disease; SD, standard deviation.International Journal of COPD 2010:5 128
Sharafkhaneh et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
utilization for every parameter examined including mean 
numbers of physician encounters (nonlaboratory vis-
its), other outpatient encounters, emergency room visits, 
acute inpatient discharges, total bed days of care, and 
  percentages of patients with any emergency room visit or any 
acute inpatient discharge compared with controls (Table 2). 
These differences applied both to respiratory-related health 
care use and health care use related to all other causes.
Furthermore, patients with COPD had significantly 
higher mean outpatient, inpatient, pharmacy, and total costs 
for both respiratory health care utilization and health care 
utilization related to all other causes compared with controls 
(Table 2). Mean respiratory-related total health care costs (the 
sum of the outpatient, inpatient, and pharmacy costs) were 
  approximately 10 times higher in patients with COPD than 
controls ($676.68 versus $68.50 per patient for the second 
year of utilization, P  0.0001).
Comorbidities
Patients with COPD had a significantly higher comorbid 
illness burden than controls (Table 3). The mean Charlson 
Comorbidity Index in patients with COPD was one point 
higher (indicating at least one comorbidity more, on average) 
than in controls (2.85 versus 1.84; P  0.0001).
Myocardial infarction, congestive heart failure, peripheral 
vascular disease, rheumatologic disease, peptic ulcer disease, 
and malignancy/lymphoma/leukemia were significantly more 
frequent in patients with COPD than in controls (Table 3).
Table 4 shows other baseline comorbid conditions for 
COPD group versus the control group.
Medications
Approximately three fifths (60.6%) of patients with COPD 
were receiving some type of respiratory medication (Table 5). 
The most common respiratory treatment was short-acting 
Table 2 Second-year utilization and cost outcomes1
Respiratory-related All other Overall
COPD Control P value COPD Control P value COPD Control P value
Health care resource use
# of physician  
encounters  
(non-lab visits)2
Mean 0.75 0.075 0.0001 4.58 3.37 0.0001 5.33 3.44 0.0001
# of other  
outpatient  
encounters2
Mean 0.17 0.01 0.0001 6.20 3.89 0.0001 6.37 3.90 0.0001
# of emergency 
room visits2
Mean 0.13 0.023 0.0001 0.48 0.250 0.0001 0.61 0.274 0.0001
Any emergency  
room visit3
n 
%
3,666 
8.56
1,666 
1.94
0.0001 
na
9,323 
21.80
11,600 
13.56
0.0001 
na
10,804 
25.25
12,277 
14.35
0.0001 
na
# of acute  
  inpatient  
discharges4
Mean 0.072 0.0059 0.0001 0.134 0.072 0.0001 0.206 0.078 0.0001
Total bed days  
of care5
Mean 4.97 1.17 0.0001 8.90 12.07 0.0001 13.87 13.24 0.0001
Any acute  
  inpatient  
discharge5
n
%
2,356
5.50
452
0.53
0.0001
na
3,651
8.53
4,199
4.91
0.0001
na
5,227
12.21
4,455
5.20
0.0001
na
Length of stay5 Mean 3.84 1.07 0.0001 5.70 8.31 0.0001 9.54 9.38 0.0001
Costs
Outpatient $ Mean 191.72 21.30 0.0001 1,616.90 1,071.31 0.0001 1,808.62 1,092.60 0.0001
Inpatient $ Mean 484.97 47.21 0.0001 2,144.09 1,126.89 0.0001 2,629.06 1,174.10 0.0001
Pharmacy $ Mean na na na na na na 1,256.10 747.10 0.0001
Total $ Mean 676.68 68.50 0.0001 3,761.00 2,198.20 0.0001 5,693.78 3,013.80 0.0001
Notes: 1This table shows utilization and costs for the time period from 366 to 730 days following the patient’s index date. For patients with COPD, the index date is the first 
date at which COPD was listed as a first or second diagnosis in either the inpatient or outpatient setting. For controls, the index date is the date of the encounter at which the 
patient was matched with a corresponding COPD patient. Patients with an index date before 10/1/1998 were not included in this table because cost data were only available 
starting on 10/1/1999. 2number and percentage of patients with one or more visits to a VA outpatient clinic. 3Mean number of days on which a patient visited one or more VA 
outpatient clinics. 4Mean number of discharges among all patients in the cohort, including those with no hospital stays. 5Total bed days of care, mean length of stay, and number 
and percentage of patients are among patients who had one or more hospital stays at a VA acute care facility.
Abbreviations: COPD, chronic obstructive pulmonary disease; nA, not available; VA, veterans Affairs.International Journal of COPD 2010:5 129
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beta-agonists, which were prescribed to 54.5% of patients 
with COPD at baseline. Less than 1% of patients with 
COPD were receiving an inhaled corticosteroid/long-acting 
beta-agonist combination at the time of diagnosis.
Discussion
In this study we have demonstrated the huge impact of 
COPD on the US VA population. Almost 1 in 10 patients in 
the southeastern US seen in the VA health care system had 
COPD. This prevalence is higher than the 42 per 1000 esti-
mated by the National Center for Vital Statistics9 but generally 
comparable to estimates from the National Heart Lung and 
Blood Institute.10 The 8.2% prevalence rate in the current 
study is consistent with previous observations suggesting that 
veterans have a higher burden of illness than nonveterans.11 
Patients with COPD compared with age-, race-, sex-, and 
index year-matched patients without COPD in this study had 
higher rates of inpatient and outpatient utilization and higher 
costs of care for respiratory conditions and all other condi-
tions. In patients with COPD compared with controls, mean 
total respiratory-related total health care costs (the sum of the 
outpatient, inpatient, and pharmacy costs) were approximately 
10 times higher, and total costs for all other conditions were 
approximately 1.7 times higher. The results suggest that the 
Table 3 Charlson Comorbidity Index and Charlson Comorbidity Index components
COPD patients (N = 59,906) Control patients (N = 117,546) P value
Charlson Comorbidity Index, mean (SD)
2.85 (1.46) 1.84 (1.52) 0.0001
Charlson comorbidity index components, n (%)
Myocardial infarction 1828 (3.05) 3103 (2.64) 0.0001
Congestive heart failure 6270 (10.47) 5937 (5.05) 0.0001
Peripheral vascular disease 3238 (5.41) 4238 (3.61) 0.0001
Cerebrovascular disease 3848 (6.42) 7701 (6.55) 0.3010
Dementia 681 (1.14) 1965 (1.67) 0.0001
Chronic pulmonary disease 59,906 (100) 0 (0) na
rheumatologic disease 992 (1.66) 1473 (1.25) 0.0001
Peptic ulcer disease 2083 (3.48) 2586 (2.20) 0.0001
Mild liver disease 518 (0.86) 981 (0.83) 0.5121
Diabetes – mild to moderate 8182 (13.66) 21,613 (18.39) 0.0001
Diabetes with chronic complications 2257 (3.77) 5573 (4.74) 0.0001
Paraplegia or hemiplegia 418 (0.70) 1074 (0.91) 0.0001
renal disease 1425 (2.38) 2672 (2.27) 0.1614
Any malignancy/lymphoma/leukemia 6367 (10.63) 11,561 (9.84) 0.0001
Moderate or severe liver disease 143 (0.24) 386 (0.33) 0.0011
Metastatic solid tumor 0 (0) 0 (0) na
Acquired immune deficiency syndrome (AIDS) 510 (0.85) 1473 (1.25) 0.0001
Abbreviations: COPD, chronic obstructive pulmonary disease; SD, standard deviation.
Table 4 Baseline other comorbidities, n (%)
COPD patients (N = 59,906) Control patients (N = 117,546) P value
Depression 6279 (10.48) 10,014 (8.52) 0.0001
Angina 3006 (5.02) 3605 (3.07) 0.0001
Cardiac dysrhythmias 5414 (9.04) 8506 (7.24) 0.0001
Pulmonary embolism 173 (0.29) 165 (0.14) 0.0001
Pneumonia 3226 (5.39) 1870 (1.59) 0.0001
Acute upper respiratory infections 6489 (10,83) 5707 (4.86) 0.0001
Otitis media 656 (1.10) 1053 (0.90) 0.0001
Disorders of lipid metabolism 613 (1.02) 1087 (0.92) 0.0439
hypertension 28,233 (47.13) 54,126 (46.05) 0.0001
Osteoporosis 723 (1.21) 677 (0.58) 0.0001
Gastroesophageal reflux disease 587 (0.98) 686 (0.58) 0.0001
Septicemia 291 (0.49) 689 (0.59) 0.0070
Alcohol/drug abuse, dependence, or poisoning 12,519 (20.90) 12,539 (10.67) 0.0001
Abbreviation: COPD, chronic obstructive pulmonary disease.International Journal of COPD 2010:5 130
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high prevalence of COPD and the excess health care resource 
use in the VA population place a substantial burden on the 
federal government to provide care for these patients.
It is difficult to compare the costs of care in this VA with 
those described in other studies due to differences in study 
designs, populations studied, and methodology used, as well 
as disparate health care systems in place. However, the VA 
system, when stacked against systems used in European 
countries, doesn’t seem as farfetched a comparison upon 
closer comparison. There are established eligibility criteria 
for enrollment, no resource-based incentives are offered, deci-
sions are formulated on the basis of evidence provision, and 
there is a strong negotiating power due to its size, as well as 
the fact that the government is involved. In fact, this system 
may be similar to national insurance health care systems seen 
in many European countries. This study therefore can add to 
the body of literature aimed at studying COPD as a disease 
and costs from the perspective of a government-based health 
care system. Studies of the costs of COPD in other countries 
corroborate results of the current study by demonstrating the 
substantial economic impact of COPD, particularly in patients 
with severe disease and/or frequent exacerbations.12–15 Costs 
reported in this study are not expenditures by the patient, but 
are derived from the VA perspective, which allocates costs to 
services from a global budget for a given year. Costs in the 
VA system vary based on the number of services provided 
(more services and lower budget mean lower average costs). 
In 2000, the mean annual Medicare expenditures in the US 
were $11,841 for patients with COPD compared with $4901 
for all covered patients.16 In a study of 6,793 Texas Medicaid 
patients with COPD, the annual costs of care totaled $11,580 
per patient.17 In the current study, total costs during the second 
year of utilization of services for patients with COPD were 
$4,437 per patient. This value is comparable to the mean 
costs of care in a study of VA patients with chronic condi-
tions.18 The costs of care in the current study are therefore 
consistent with those described in previous VA populations 
but substantially lower than those in patient populations from 
other health care systems in the United States.
The high frequency of comorbid conditions adds to the 
disease and cost burden in the VA population. This finding 
corroborates other research conducted in non-US patients 
not selected with respect to veteran status.19 In the current 
study, patients with COPD compared with controls were 
significantly more likely to have comorbidities including 
chronic debilitating or life-threatening diseases. The high 
frequency of comorbidities in veterans with COPD has been 
described in other studies.5,6 In a study of 70,679 patients 
with COPD hospitalized at a VA hospital in 1998, the 
prevalence of cardiovascular comorbidities substantially 
exceeded that in an age- and gender-matched cohort without 
COPD at 33.6% versus 27.1% for coronary artery disease, 
24.4% versus 13.5% for congestive heart failure, and 14.3% 
versus 10.4% for atrial fibrillation.5 Comorbidities can also 
increase the risk of poor outcomes following an exacerba-
tion of COPD. A study of 51,353 patients discharged after 
an exacerbation of COPD in the VA system identified 
pulmonary hypertension and weight loss as risk factors 
for death.6
In a recent study of 6,793 Texas Medicaid patients 
with COPD,17 the mean Charlson Comorbidity Index was 
  approximately 1.9, a value similar to that seen in the control 
cohort but approximately one point lower than that seen in 
the COPD cohort in the current study. Furthermore, 7% 
of COPD patients in that study were hospitalized for any 
cause versus 14.0% in the current study, although 83% of 
the Medicaid patients had emergency department visits 
versus 30.4% in the current study. Patients in the current 
study were more likely to be seen in the inpatient setting, 
an observation that suggests greater severity of illness 
among patients with COPD in this study than in the Texas 
Medicaid study.
Perhaps the most striking finding in the current study 
is the seeming undertreatment of the COPD population. 
Approximately 40% of patients were not receiving any 
of the medications recommended in global treatment 
  guidelines20 at baseline. The most common respiratory 
medication prescribed for these patients with COPD was 
short-acting beta-agonists, which according to treatment 
Table 5 Baseline respiratory pharmacotherapies among patients 
with COPD
n % of total 
59,906
% of 
treated 
36,285
Treated1 36,285 60.6 100.0
    Inhaled corticosteroid+long-acting 
beta-agonist combination, any
449 0.7 1.2
    Inhaled corticosteroid+long-acting 
beta-agonist combination 250/50
261 0.4 0.7
    Inhaled corticosteroid 11,177 18.6 30.8
  Short-acting beta-agonist 32,629 54.5 89.9
  Long-acting beta-agonist 2,176 3.6 6.0
    Short- or long-acting  
anticholinergic
13,493 22.5 37.2
untreated2 23,621 39.4 na
Notes: 1Defined as receiving medications in these drug class groups within 90 days 
before or after the index date. 2not treated with any of these groups.
Abbreviation: COPD, chronic obstructive pulmonary disease.International Journal of COPD 2010:5 131
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guidelines are to be used as rescue medications and not 
as maintenance treatment. Maintenance treatment with 
guidelines-recommended long-acting bronchodilators was 
prescribed in the minority of patients in the current study. 
These findings are consistent with results of studies from 
Canada, Japan, and Europe, in which patients were not 
selected based on veteran status.21–24
Strengths of the current study include the large sample 
size and the examination of patients in a federally funded and 
operated integrated managed care system. As VA physicians 
are salaried and as Congress determines the total VA health 
care budget, few negative incentives operate either to limit 
care for VA patients or to exaggerate the illness burden in 
order to garner more resources. The results of the current 
study therefore are likely to reflect actual illness burden 
and health care use for these patients. The matched case-
control design, which contributes to good internal validity, 
lends strength to the rigor of this study. The matched design 
allowed the utilization and cost measures to be adjusted for 
demographic, temporal, and contextual variables to reduce 
confounding.
Codes for bronchiectasis and allergic alveolitis were 
included in the ICD-9-CM-based definition of COPD in 
this study. Patients with bronchiectasis usually present with 
frequent infections and airflow obstruction and are treated 
similarly to patients with COPD. Patients with allergic 
alveolitis usually present with symptoms similar to those 
of COPD. Because these cases were so few in number 
(0.15%), they are unlikely to have affected the results. 
Notably, multiple diagnosis fields are included on medical 
claims in VA administrative data. In the very few cases of 
  bronchiectasis and allergic alveolitis that were observed, 
COPD was also present on these medical claims. The clinical 
reasons explained above did not permit a clear rationale for 
excluding these cases.
This study has certain limitations inherent to retrospective 
observational studies involving claims data. Accuracy and 
completeness of diagnosis codes cannot be verified. How-
ever, the VA has relatively complete utilization records and is 
less susceptible to problems of coding bias that may occur in 
other managed care systems. The reliance of this study on VA 
pharmacy prescription fill records for estimates of medication 
use is a limitation that could have led to underestimation of 
medication use. The records do not contain information on 
out-of-plan (non-VA) prescriptions, such as Medicaid or 
Medicare or private insurance, for which the veteran may 
be eligible, nor do they capture over-the-counter pharmacy 
use. While the extent of out-of-plan or out-of-network 
pharmacy use cannot be determined, it is thought to have 
been relatively infrequent. Also, the pharmacy prescription 
records for this study were obtained only from VISN 16 data 
warehouse records and did not include VA prescription fills 
outside of VISN 16. The data were obtained from a primarily 
male VA population and cannot be generalized to women or 
nonveterans. Although comorbidities play a role in overall 
cost burden to the VA system, comorbid conditions can also 
increase COPD complexity pathologically and in economic 
terms. For example, having cardiovascular disease may make 
COPD exacerbations more common; therefore, having that 
comorbidity will increase the costs involved with treating 
COPD as well. Therefore, it may not be entirely accurate to 
say that all those costs are part of a global chronic burden 
for patients. Admittedly, lack of functional data prevents 
conclusive exploration of this issue. Another limitation 
may be lack of adjustment for presence of comorbidities. 
In the absence of objective lung function data (absent in 
  administrative claims databases such as the VA), one cannot 
say with complete certainty whether rates of maintenance 
treatment were indeed lower. This is a limitation found 
in administrative claims databases like the VA system. 
Finally, the study was conducted in the United States, and 
the generalizability of the results to other countries is not 
known. However, as discussed earlier, the VA system design 
is similar to countries in Europe that have national health 
care models. Therefore, there is possibility that the results 
from this study are applicable to those countries. Within the 
United States, however, the VA system is very different from 
closed network health maintenance organizations (HMOs), 
  commercial health plans, and federally funded Medicare and 
Medicaid programs.
In conclusion, veterans with COPD compared with those 
without COPD suffer a tremendous disease burden with high 
rates of all-cause and respiratory-related health care utiliza-
tion and higher health care costs. Furthermore, a significant 
  number of these patients remain untreated, a finding corrobo-
rating data from other studies.21,22,25 The results underscore the 
undertreatment of COPD in the current health care system. 
Future researchers should examine treatment strategies and 
interventions that may help reduce the burden of COPD in 
the veterans population.
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